TMTat'YAna Ivanovna Moiseenko

Tat'YAna Ivanovna Moiseenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tat'YAna Ivanovna Moiseenko has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Features of mitochondrial hormone and receptor levels in aggressive endometrial cancer subtypes

    by E. M. Frantsiyants, V. A. Bandovkina, E. I. Surikova, A. P. Menshenina, T. I. Moiseenko, E. A. Ozerkova, I. V. Neskubina, A. I. Shikhlyarova, N. D. Cheryarina, M. A. Rogozin

    Serous endometrial carcinoma (SEC) and clear cell endometrial carcinoma (CCEC) are among the most aggressive subtypes of endometrial cancer (EC), characterized by a high risk of recurrence and metastasis. Mitochondria play a key role in steroidogenesis and cellular metabolism; however, their contribution to hormonal and metabolic tumor adaptation in rare forms of EC remains poorly understood. Purpose of the study . To comprehensively assess the levels of sex hormones, their receptors, cortisol, and glutathione in mitochondria isolated from SEC and CCEC tissues.Patients and methods. This prospective study included 41 patients with rare forms of EC. Mitochondria were isolated from tumor tissues – 21 SEC and 20 CCEC. The control group was composed of 20 samples of endometrium unaffected by tumour. Concentrations of estrone, estradiol, estriol, testosterone, progesterone, estrogen receptors (REα, REβ), androgen receptors, progesterone receptors (RP4), cortisol, cholesterol, and glutathione were determined by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using Statistica 10.0 software. Results . In mitochondria obtained from SEC and CCEC, compared with tumor-free endometrial mitochondria, levels of testosterone and progesterone were increased by an average of 1.5‑fold, estriol by 1.8‑fold and 2.2‑fold, REβ by 3.5‑fold and 1.8‑fold, RP4 by 2.4‑fold and 5.2‑fold, and the REβ/REα ratio by 2.2‑fold and 1.9‑fold, respectively. Estradiol, REα, and androgen receptor levels exceeded control values only in SEC mitochondria, by 2.0‑fold, 1.8‑fold, and 2.2‑fold, respectively. Cortisol and cholesterol concentrations in mitochondria from rare endometrial cancer subtypes were 1.9–2.5‑fold higher than in tumor-free endometrial mitochondria, while glutathione levels were increased by 1.9–2.4‑fold. Conclusion . SEC and CCEC are characterized by the formation of a unique mitochondrial hormonal microenvironment with estriol predominance and a high REβ/REα ratio, which may mediate suppression of apoptosis and enhanced proliferation. Differences in receptor profiles indicate distinct mechanisms of hormonal signaling, potentially determining specific features of the clinical course of each tumor subtype. Accumulation of cholesterol and cortisol in the context of elevated glutathione levels indicates metabolic reprogramming aimed at sustaining steroidogenesis and resistance to oxidative stress and apoptosis.

  • Open Access

    Dendritic cell vaccines in immunotherapy of gynecological malignancies: current strategies and clinical perspectives

    by E. M. Frantsiyants, V. A. Bandovkina, I. V. Neskubina, A. P. Menshenina, T. I. Moiseenko, E. A. Ozerkova, E. I. Surikova, A. I. Shikhlyarova

    Immunotherapeutic vaccines are a promising direction in the treatment of oncological diseases. In recent years, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. Aim of the study was to systematize modern data on the development and clinical use of dendritic cell (DC) vaccines for the treatment of gynecological cancer, evaluate their effectiveness, identify key limitations and promising strategies for enhancing the antitumor response. Material and methods. The PubMed, Google Scholar and eLIBRARY.RU databases were used to write the literature review. Results. Clinical studies demonstrate that DC vaccines are capable of inducing a specific antitumor immune response, increasing relapse-free and overall survival in patients with gynecological cancers. The greatest efficiency is observed in combination with chemotherapy, especially when using personalized vaccines based on autologous tumor lysates or neoantigens. However, limitations to their widespread use include response heterogeneity, manufacturing complexity, and the need to optimize the timing of administration relative to other treatments. Conclusions. DC vaccines represent a promising direction for immunotherapy of gynecologic malignancies, but require further research to overcome current limitations. The development of personalized approaches and combination strategies could significantly improve their clinical effectiveness.

  • Application of dendritic cell vaccine immunotherapy in gynecologic malignancies

    by G. V. Zhukova, E. M. Frantsiyants, I. V. Kapliyeva, T. I. Moiseenko, A. P. Menshenina, A. I. Shikhlyarova, V. A. Bandovkina, E. I. Surikova, E. V. Shalashnaya, Y. A. Petrova, et al.

    The development of antitumor strategies aimed at restoring systemic and local immune regulation is considered one of the most promising directions. Technologies based on dendritic cell vaccines (DCVs), characterized by minimal toxicity and alignment with fundamental immunological mechanisms of antitumor resistance, are of particular interest. Purpose of the study . Is to evaluate the effectiveness of immunotherapeutic approaches for gynecologic malignancies using DCVs and to outline promising directions for further development. Materials and methods. A literature search was conducted in the bibliographic registers MEDLINE, ClinicalTrial.gov., eLIBRARY and CyberLeninka, using the search systems PubMed, Google Scholar. The vast majority of the identified sources are indexed in Scopus and Web of Science. The review includes more than 60 publications in Russian and English, over 50 % of which were published within the past five years. Results. The analysis summarizes data on the clinical outcomes of DCV-based therapy in advanced cervical cancer, endometrial cancer, and ovarian cancer. Reported beneficial effects include temporary disease stabilization, improved overall survival and quality of life in advanced malignancies, enhanced efficacy of subsequent chemotherapy, and occasional cases of partial or complete remission. The review also addresses potential reasons for the limited efficacy of DCVs, as well as possible combinations of this technology with other immunotherapeutic modalities and traditional anticancer treatments. The currently modest therapeutic effectiveness of DCVs in gynecologic cancers may be attributed both to the insufficient maturity of the technology and to inherent mechanisms of tumor immune evasion. Conclusion. The therapeutic potential of DCVs has not yet been fully realized. Advances in immunotherapy, molecular biology, nanotechnology, and strategies for activating systemic and local antitumor resistance mechanisms provide a foundation for defining future research priorities aimed at improving the efficacy of DCVs as an important component of multimodal treatment for gynecologic malignancies.

  • The content of steroid hormones in the mitochondria of unchanged and tumor tissue of the uterine body

    by E. M. Frantsiyants, V. А. Bandovkina, T. I. Moiseenko, A. P. Menshenina, Yu. A. Petrova, I. V. Neskubina, L. K. Trepitaki, E. I. Surikova, M. A. Rogozin, N. D. Cheryarina, et al.

    Mitochondria regulate a wide range of processes, including stress responses, metabolism, immunity, differentiation, redox homeostasis, and steroidogenesis, and also serve as the principal intracellular source of reactive oxygen species (ROS). Mitochondrial dysfunction has been linked to the development of various pathological conditions, including the growth of both benign and malignant tumors. Purpose of the study . Determination of the level of steroid hormones in the mitochondria of various tissues of the uterine body. Materials and methods . The study included 65 patients with benign and malignant diseases of the uterus: 25 patients with endometrioid adeno‑ carcinoma of the uterus (EAC) of low differentiation (G3) stage II–III; 15 patients with leiomyosarcoma of the uterus stage I–III; and 25 patients with uterine myoma. Mitochondria from native samples of uterine tumors were isolated by differential centrifugation in a high-speed refrigerated centrifuge Avanti J-E, Becman Coulter. For the comparison group, mitochondria were isolated from intact uterine tissue. The levels of estradiol (E2), testosterone (T), progesterone (P4), and cortisol were determined using standard ELISA kits (Monobind, USA) in mitochondria isolated from the indicated tissues. A statistical analysis of the results was conducted using the Statistica 10.0 software package. Results. Irrespective of the nature of the tumor process (benign or malignant), a decrease in the P4 level by 2.7 to 9.1 times, but an increase in the content of cortisol by 1.3 to 3.7 times and T by 2.1 to 3.7 times were detected in the mitochondria of uterine tumors. Conversely, the concentration of E2 in the mitochondria of uterine fibroids exhibited an increase of 2.2 times compared to the indicators in the mitochondria of the intact uterus. No significant differences were observed in the mitochondria of EAC, while a decrease of 1.4 times was noted in the mi‑ tochondria of uterine sarcoma. Conclusion . There is a change in the content of steroid hormones in In the mitochondria of uterine tumors, consisting in an increase in the concentrations of cortisol and testosterone and progesterone deficiency regardless of the type of pathology, but a relative or absolute defi‑ ciency of estrogens only in the mitochondria of malignant tumors. Changes in the steroid background of tumor mitochondria, compared with the mitochondria of the intact uterus, probably have a significant effect on both the energy balance of cells and the production of ROS, as well as on proliferative processes.

  • Open Access

    Study of the intensity of free radical oxidation in mitochondria of endometrioid adenocarcinoma cells depending on the degree of tumor differentiation

    by E. M Frantsiyants, I. V. Kaplieva, I. V. Neskubina, A. I. Shikhlyarova, Yu. A. Petrova, L. K. Trepitaki, V. A. Bandovkina, E. I. Surikova, T. I. Moiseenko, M. L. Adamyan, et al.

    Purpose of the study . To investigate redox-balance parameters in mitochondria of endometrioid adenocarcinoma (EA) cells in oncogynecological patients, as well as in mitochondria of Guerin carcinoma cells with intramural tumor localization in rats. Materials and methods . The clinical part of the study included patients who underwent surgical treatment for EA (n = 42) and uterine fibroids (n = 14). Among patients with EA, 16 had well-differentiated tumors (G1), 12 had moderately differentiated tumors (G2), and 14 had poorly differentiated tumors (G3). The mean age of patients with EA was 60.8 ± 2.9 years, and with fibroids – 49.4 ± 2.5 years. None of the patients received neoadjuvant therapy. The experimental part of the study included biological material obtained from non-linear white female laboratory rats (n = 15) weighing 250 ± 25 g. Intramural growth of Guerin carcinoma was reproduced in these animals. In mitochondria isolated from EA, fibroid, and intact uterine tissues, concentrations of the following parameters were determined using standard ELISA methods: mitochondrial superoxide dismutase (SOD‑2), DNA and RNA oxidative modification products, malondialdehyde (MDA), diene conjugates (DC), and total protein (biuret method). Statistical analysis was performed using Statistica 10.0. Results . In women, mitochondria of EA cells in G1 tumors demonstrated a markedly elevated content of MDA and DC – 2.3‑fold and 2.9‑fold higher, respectively, compared with values in mitochondria of intact uterine tissue. In G2 tumors, MDA levels were 3.2‑fold higher and DC levels 2.7‑fold higher than in intact mitochondria. In G3 tumors, the degree of DNA damage increased 1.6‑fold (p < 0.05), while MDA, DC, and SOD‑2 concentrations increased 2.4‑fold, 3.0‑fold, and 3.4‑fold, respectively, compared with intact values. In female rats, mitochondria isolated from tumor tissues with intramural Guerin carcinoma growth displayed changes similar in direction to the clinical results: DNA damage increased 1.6‑fold (p < 0.05), MDA 1.6‑fold (p < 0.05), DC 1.5‑fold (p < 0.05), and SOD‑2 2.4‑fold. Conclusion . The oxidative stress and mitochondrial dysfunction identified in malignant cells of women indicate a differentiationdependent pathogenetic feature. Additionally, an identical direction of redox-balance alterations was demonstrated in the experimental subcellular model, supporting the translational relevance of the findings.


  • Open Access

    Possibilities of Adaptation Processes Disorders Correction in Patients with Uterine Cancer in the Perioperative Period

    by S. V. Tumanyan, T. I. Moiseenko, E. M. Frantsiyants, E. M. Nepomnyashchaya, S. S. Tumanyan, A. A. Gretskaya, К. А. Екимовский, I. Kh. Murtazalieva, K. V. Artsatbanova, M. A. Bagautdinova

       Background. It is well known that patients with uterine cancer (UC) experience disturbances in adaptation processes during the surgical stage of treatment, which are especially pronounced in the perioperative period. These phenomena have almost never been studied, but they exist and require the use of therapeutic agents capable of influencing the systemic adaptive-regulatory control mechanisms involved in the pathological process. Such agents include the metabolic drug Remaxol®, one of the possible mechanisms of which is the formation of adaptive homeostasis by increasing the pool of general non-specific adaptive reactions (GNAR) of the physiological type.   The aim of the study was to determine the effect of Remaxol® on the possibility of forming adaptive reactions and correcting adaptive homeostasis in patients with UC in the perioperative period.   Material and methods. The prospective study included 72 patients with verified UC, aged 56–72 years. All patients were comparable by age, extent of the process, anthropometry, and were randomly distributed into the main(N = 39) and control groups (N = 33). In the main group, Remaxol® (inosine + meglumine + methionine + nicotinamide + succinic acid) was included in therapeutic support in order to compensate for regulatory-adaptive mechanisms. It was administered intraoperatively and during the first 4 days of the perioperative period. Remaxol® was not prescribed in the control group. The structure and type of GNAR characterizing the adaptation status, its systemic interrelations, the level of reactivity in quantitative terms, were identified based on the morphological composition of the blood.   Results. The main types of general adaptive reactions and their structure in UC patients were determined. An analysis of GNAR development was carried out when Remaxol® was included in the perioperative treatment program. It was shown that its use in the system of therapeutic measures reduces the impact of surgical stress in the perioperative period.   Conclusion. The use of Remaxol® promotes the sustainable development of a sufficient number of anti-stress reactions of physiological orientation, as well as high resistance with subsequent stabilization of adaptive homeostasis in UC patients in the perioperative period.

  • MODERN CONCEPTS FOR ANTITUMOR VACCINE DESIGN

    by Elena Mikhailovna Frantsiyants, Valeriya Akhtyamovna Bandovkina, Irina Valer'EVna Neskubina, Anna Petrovna Men'SHenina, Ekaterina Igorevna Surikova, Tat'YAna Ivanovna Moiseenko

    Immunotherapeutic vaccines represent a promising strategy in oncology. Recently, significant progress has been made in understanding the mechanisms of interaction between the immune system and tumor cells and in developing strategies to overcome tumor immunosuppression. The aim of the review is to systematize modern data on approaches to the development of antitumor vaccines, analyze their mode of action, advantages and limitations. Materials and methods. The PubMed, Google Scholar and eLibrary.ru were used for literature review. Results. The review considers various platforms for creating antitumor vaccines: dendritic and tumor cells, nucleic acids, oncolytic viruses and peptides. Nucleic acid vaccines (DNA/mRNA) can encode multiple epitopes, including neoantigens, and are easily adapted for personalized therapy. Viral and cellular platforms combine direct tumor lysis with immunostimulation. Research papers present modern methods on modifying tumor cells to enhance their immunogenicity, such as adjuvant therapy, genetic engineering, and antigen delivery platforms. The review highlights the prospects for using exosomes and mitochondria as carriers for delivering therapeutic molecules, as well as combined approaches that include the use of vaccines in combination with immune checkpoint inhibitors, cytokine-induced killer cells and radiation therapy, which helps to overcome tumor resistance to immunotherapy and enhance antitumor immunity. The problems associated with antitumor vaccines in elderly patients are discussed. Conclusion. Modern antitumor vaccines show significant therapeutic potential, particularly in combination with other treatment modalities. Successful integration of vaccines into complex cancer therapy requires interdisciplinary collaboration and continued basic and clinical research. Further research should be aimed at optimizing combination therapy regimens, developing response biomarkers, and adapting vaccines for elderly patients.

  • Open Access

    Lymph nodes as a target for the use of dendritic cell vaccines: modern approaches and prospects

    by E. M. Frantsiyants, V. A. Bandovkina, T. I. Moiseenko, Yu. A. Petrova, I. A. Goroshinskaya, G. V. Zhukova, L. K. Trepitaki, E. I. Surikova

    This article provides an overview of current approaches to cancer immunotherapy, with an emphasis on the role of dendritic cells (DCs), lymph nodes (LNs), and innovative methods of vaccine delivery. Immunotherapy using DC-based vaccines represents a promising direction, capable of stimulating a specific immune response against tumor cells and forming long-term immune memory. Tumor-draining lymph nodes (TDLNs) play a key role in immune activation, as they are the sites where dendritic cells present tumor antigens and activate T-cells. In cancer, unlike viral infections, CD8+ T-cell activation occurs in two stages, and the effectiveness of this process depends on signals from the tumor microenvironment, which explains why the immune response to cancer is often weak.The article also discusses modern strategies for delivering vaccines to lymph nodes, including the use of nanoparticles, bioorthogonal reactions, and photothermally induced materials. These approaches help overcome the "granularity paradox", associated with the need to balance vaccine size for LN penetration and uptake by immune cells. The prospects of adoptive cell therapy using T-cells from TDLNs, as well as the role of exosomes and whole-cell tumor antigens in the development of effective vaccines, are also considered. Combination strategies, such as the use of vaccines together with checkpoint inhibitors (e. g., anti-PD1), demonstrate potential for enhancing antitumor immunity.The further advancement of cancer immunotherapy requires the integration of new knowledge about the biology of dendritic cells, modern methods of cell engineering, and nanotechnology to create personalized and effective antitumor vaccines.


  • Open Access

    Features of some growth factors content in tumors and blood plasma in patients with rare forms of endometrial cancer

    by E. M. Frantsiyants, V. A. Bandovkina, T. I. Moiseenko, A. P. Menshenina, M. A. Rogozin, I. V. Kaplieva, E. I. Surikova, I. V. Neskubina, Yu. A. Petrova, N. D. Cheryarina, et al.

    Purpose of the study. The objective of the present study was to examine the levels of TGFβ1, EGF, and EGFR in the blood and tissue of morphologically distinct endometrial tumors, including uterine serous carcinoma (USC), clear cell endometrial cancer (CCEC), and G3 endometrioid adenocarcinoma (EAC).Patients and methods. The study encompassed 61 patients diagnosed with uterine body cancer, including 21 patients with USC, 20 patients with CCEC, and 20 patients with EAC (G3). All patients underwent a thorough morphological verification of the disease, as documented in the postoperative report. The level of epidermal growth factor and its receptor (EGF and EGFR), as well as transforming growth factor (TGFb1), was determined in cytosolic fractions of 10 % tumor homogenates and blood samples using standard ELISA kits. Samples of intact endometrium obtained from patients who underwent surgery for uterine fibroids (n = 20) and blood samples from conditionally healthy women (n = 20) of the same age served as normal indicators. Statistical analysis of the results was performed using the Statistica 10.0 software package.Results. EAC (G3) was characterized by an increased, compared to the healthy, content of growth factors and their receptors in tumor and blood samples. In tumor samples of CCEC and USC, the level of TGFβ1 was lower by 2.2 times and 1.6 times, respectively, and the concentration of EGF was on average more than 2 times lower, compared to the indicators in the intact endometrium. The content of these same growth factors in blood samples in patients with rare forms of EC exceeded the normative values by 2.1–4.2 times.Conclusion. The investigation revealed that low levels of EGF were present in tumor samples of rare forms of endometrial cancer, accompanied by unaltered levels of EGFR and TGFβ1. This observation stands in contrast to the elevated concentrations of these growth factors detected in blood samples. The distinctive profile of these growth factors in tumor samples differentiates them from the indicators observed in EAC tissue, where the levels of EGFR and TGFβ1 are augmented. It is plausible that the altered metabolism of non-endometrioid uterine cancers leads to alterations in the biological characteristics of tumors, consequently resulting in a more aggressive clinical course.

  • Open Access

    Possibilities of Correcting Energy Metabolism Disorders and Adaptive Homeostasis in the Perioperative Period in Patients with Uterine Cancer

    by S. V. Tumanyan, T. I. Moiseenko, E. M. Franziyants, E. M. Nepomnyashya, V. A. Bandovkina

       The aim of the study was to evaluate energy metabolism and adaptation potential, as well as the possibility of their differentiated correction in energy-deficient states in the postoperative period in patients with uterine body cancer.   Methods. The patients were divided into the main (N = 36) and control groups (N = 32) immediately before the surgery. In the main group, Remaxol® was introduced into the complex of treatment measures to correct energy metabolism before and during the perioperative period. An antihypoxant was not used in the control group. The state of energy metabolism and the type of energy deficiency were assessed by hemoglobin transport, oxygen consumption and extraction, glucose and lactate concentrations. The quantitative and qualitative composition of peripheral blood was studied in order to determine the nature of the adaptive response. The survey was conducted before surgery, on the 2nd and 5th days of the perioperative period.   Results. 69 % of patients had G1 differentiation of endometrial carcinoma. Excess weight > 26) was recorded in 68% of cases, regardless of the uterine body cancer (UBC) stage. Patients are comparable in age, as well as anthropometry. Analysis of the obtained results showed that the baseline background of UBC patients is characterized by various types of dysregulation of energy metabolism, disruption of the regulatory mechanisms of the physiological adaptation response, and the prevalence of the body's stress response. The use of Remaxol® contributed to the restoration of energy potential and adaptive homeostasis in the main group of patients in the perioperative period.   Conclusion. A differentiated approach to the dose selection of the anti-hypoxant used in this category of patients promotes leveling of emerging types of energy deficiency, restoration of adequate oxygen consumption and extraction, hemoglobin transport, remodulation of physiological adaptive homeostasis regulatory mechanisms, which will contribute to a favorable course of the perioperative period, as well as a decrease in the number of somatic and surgical complications in this category of patients.